INO

Inovio Pharmaceu

• Dow Jones·06/03 20:34

  Inovio Pharmaceuticals Inc. Stock Falls 5.8%, Underperforms Peers

• Dow Jones·06/02 20:35

  Inovio Pharmaceuticals Inc. Stock Falls 5.5%, Underperforms Peers

• Dow Jones·06/01 11:10

  Inovio Pharma Is Maintained at Neutral by HC Wainwright & Co.

• Dow Jones·06/01 11:10

  Inovio Pharma Price Target Cut to $2.50/Share From $3.00 by HC Wainwright & Co.

• Benzinga·06/01 11:00

  HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

• TipRanks·06/01 10:38

  Inovio price target lowered to $2.50 from $3 at H.C. Wainwright

• Dow Jones·05/26 20:33

  Inovio Pharmaceuticals Inc. Stock Slips 6.7%, Underperforms Peers

• NASDAQ·05/25 18:02

  Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

• Seeking Alpha·05/22 16:35

  Inovio gains on late-stage trial win for DNA shot

• TipRanks·05/22 11:20

  Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)

• Dow Jones·05/21 20:33

  Inovio Pharmaceuticals Inc. Stock Advances 8.1%, Outperforms Peers

• TipRanks·05/21 20:21

  Inovio: ApolloBio announces ‘positive’ results from Phase 3 trial of VGX-3100

• Benzinga·05/21 20:09

  Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile

• PUBT·05/21 20:06

  Inovio partner ApolloBio says VGX-3100 Phase 3 cervical dysplasia trial hits endpoint

• Reuters·05/21 20:05

  INOVIO PHARMACEUTICALS INC - VGX-3100 PHASE 3 TRIAL MEETS PRIMARY ENDPOINT WITH FAVORABLE SAFETY PROFILE